

Step Therapy Approval Criteria

Effective Date: 01/01/2021

This document contains Step Therapy Approval Criteria for the following medications:

- 1. Armour Thyroid (porcine thyroid)
- 2. Banzel (rufinamide)
- 3. Baqsimi (glucagon nasal powder)
- 4. Belsomra (suvorexant)
- 5. Biktarvy (bictegravir/emtricitabine/tenofovir)
- 6. Breo Ellipta (fluticasone/vilanterol)
- 7. Brilinta (ticagrelor)
- 8. Bydureon (exenatide)
- 9. Cequa (cyclosporine)
- 10. Colcrys (colchicine)
- 11. Combigan (brimonidine/timolol)
- 12. Combipatch (estradiol/norethindrone)
- 13. Contrave (naltrexone/bupropion)
- 14. Corlanor (ivabradine)
- 15. Dexilant (dexlansoprazole)
- 16. Dovonex (calcipotriene)
- 17. Dulera (mometasone/formoterol)



- 18. Eliquis (apixaban)
- 19. Enbrel (etanercept)
- 20. Envarsus XR (tacrolimus extended-release)
- 21. Estring (estradiol vaginal ring)
- 22. Estrogel (estradiol)
- 23. Eucrisa (crisaborole)
- 24. Femring (estradiol)
- 25. Fiasp (insulin aspart, recombinant)
- 26. Humira (adalimumab)
- 27. Imitrex Injection vial and STATdose (sumatriptan succinate)
- 28. Invokana (canagliflozin)
- 29. Jardiance (empagliflozin)
- 30. Levitra (vardenafil)
- 31. Lumigan (bimatoprost)
- 32. Mydayis (dextroamphetamine/amphetamine)
- 33. Myrbetriq (mirabegron)
- 34. Nucynta (tapentadol)
- 35. Nucynta ER (tapentadol extended-release)
- 36. Onfi (clobazam)
- 37. Ozempic (semaglutide)
- 38. Pristiq (desvenlafaxine succinate)
- 39. Protopic (tacrolimus)
- 40. Qbrexza (glycopyrronium)
- 41. Risperdal Consta (risperidone long-acting injection)
- 42. Tirosint (levothyroxine)
- 43. Toujeo Solostar and Toujeo Max Solostar (insulin glargine)
- 44. Trelegy Ellipta (fluticasone/vilanterol/umeclidinium)
- 45. Vimpat (lacosamide)
- 46. Vyvanse (lisdexamfetamine)
- 47. Vyzulta (latanoprostene)
- 48. Xifaxan (rifaximin)
- 49. Xiidra (lifitegrast)



Step Therapy Approval Criteria Armour Thyroid (porcine thyroid)

Generic name: porcine thyroid **Brand name:** Armour Thyroid

Medication class: Thyroid

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of levothyroxine tablets in the past 365 days.

Formulary Management Review: Initial: February 2020



Step Therapy Approval Criteria Banzel (rufinamide)

Generic name: rufinamide

Brand name: Banzel

Medication class: Anticonvulsant

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

- Previous failure of both of the following in the past 365 days:
 - o Lamotrigine
 - o Topiramate

Step 2:

• Previous failure of clobazam in the past 365 days.

Formulary Management Review: Initial: November 2019 Revision:



Step Therapy Approval Criteria Baqsimi (glucagon nasal powder)

Generic name: glucagon nasal powder

Brand name: Baqsimi

Medication class: Antihypoglycemic

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of Glucogon Emergency Kit or Glucagen Hypokit in the past 365 days.

Formulary Management Review: Initial: February 2020 Revision:



Step Therapy Approval Criteria Belsomra (suvorexant)

Generic name: suvor exant
Brand name: Belsomra
Medication class: Hypnotic

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

- Previous failure of two of the following in the past 365 days:
 - Eszopiclone
 - o Silenor
 - o Temazepam
 - o Trazodone
 - o Zolpidem

Formulary Management Review: Initial: October 2019

Revision: February 2020, October 2020



Step Therapy Approval Criteria Biktarvy (bictegravir/emtricitabine/tenofovir)

Generic name: bictegravir/emtricitabine/tenofovir

Brand name: Biktarvy

Medication class: HIV

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

- Previous failure of one of the following regimens in the past 365 days:
 - o Dovato
 - o Genvoya
 - o Triumeq
 - Tivicay with Descovy
 - o Isentress HD with Descovy

Formulary Management Review:

Initial: November 2019 Revision: February 2020



Step Therapy Approval Criteria Breo Ellipta (fluticasone/vilanterol)

Generic name: fluticasone/vilanterol

Brand name: Breo Ellipta

Medication class: Inhaled glucocorticoid/long-acting beta-agonist

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Previous failure of both of the following in the past 365 days

- Fluticasone/salmeterol (generic Advair Diskus) or Advair HFA
- Budesonide/formoterol (generic Symbicort)

Formulary Management Review: Initial: April 2020 Revision:



Step Therapy Approval Criteria Brilinta (ticagrelor)

Generic name: ticagrelor
Brand name: Brilinta
Medication class: Antiplatelet

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of clopidogrel in the past 365 days.

Formulary Management Review:

Initial: May 2020



Step Therapy Approval Criteria Bydureon (exenatide)

Generic name: exenatide **Brand name:** Bydureon

Medication class: GLP-1 receptor agonist

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of Trulicity in the past 365 days.

Formulary Management Review:

Initial: May 2020



Step Therapy Approval Criteria Cequa (cyclosporine)

Generic name: cyclosporine ophthalmic solution

Brand name: Cequa

Medication class: Calcineurin inhibitor

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of Restasis in the past 365 days.

Formulary Management Review: Initial: February 2020 Revision:



Step Therapy Approval Criteria Colcrys (colchicine)

Generic name: colchicine **Brand name:** Colcrys

Medication class: Antigout; antiinflammatory

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

- Previous failure of one of the following in the past 365 days:
 - o A formulary NSAID
 - o A formulary glucocorticoid
 - Allopurinol
 - o Probenecid/colchicine

Additional considerations:

• Quantity Limit (QL) of 60 tablets per 30 days

Formulary Management Review: Initial: October 2016 Revision:



Step Therapy Approval Criteria Combigan (brimonidine/timolol)

Generic name: brimonidine/timolol

Brand name: Combigan

Medication class: Glaucoma agent

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of brimonidine eye drops or timolol eye drops in the past 365 days.

Formulary Management Review:

Initial: May 2020



Step Therapy Approval Criteria Combipatch (estradiol/norethindrone)

Generic name: estradiol/norethindrone transdermal patch

Brand name: Combipatch

Medication class: Hormone replacement therapy

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

- Previous failure of one of the following in the past 365 days:
 - o Estradiol/norethindrone oral tablets
 - o Estradiol transdermal patches
 - o Estradiol vaginal cream

Formulary Management Review: Initial: May 2020 Revision:



Step Therapy Approval Criteria Contrave (naltrexone/bupropion)

Generic name: naltrexone/bupropion

Brand name: Contrave
Medication class: Anorexiant

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

• Previous failure of phentermine in the past 365 days.

Formulary Management Review: Initial: April 2020 Revision:



Step Therapy Approval Criteria Corlanor (ivabradine)

Generic name: ivabradine **Brand name:** Corlanor

Medication class: Cardiovascular agent

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

- Previous failure of one formulary beta-blocker in the past 365 days:
 - o Atenolol
 - o Carvedilol
 - o Labetalol
 - Metoprolol
 - Nadolol
 - o Pindolol
 - o Propranolol
 - Sotalol

Formulary Management Review: Initial: April 2020 Revision:



Step Therapy Approval Criteria Dexilant (dexlansoprazole)

Generic name: dexlansoprazole

Brand name: Dexilant

Medication class: Proton pump inhibitor

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

- Previous failure of all of the following in the past 365 days:
 - o Omeprazole
 - o Pantoprazole
 - o Esomeprazole

Formulary Management Review: Initial: February 2020 Revision:



Step Therapy Approval Criteria Dovonex (calcipotriene)

Generic name: calcipotriene

Brand name: Dovonex

Medication class: Antipsoriatic, Synthetic Vitamin D3

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of a formulary topical corticosteroid in the past 365 days

Formulary Management Review: Initial: January 2016 Revision:



Step Therapy Approval CriteriaDulera (mometasone/formoterol)

Generic name: mometasone/formoterol

Brand name: Dulera

Medication class: Inhaled glucocorticoid/long-acting beta-agonist

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Previous failure of both of the following in the past 365 days

- Fluticasone/salmeterol (generic Advair Diskus) or Advair HFA
- Budesonide/formoterol (generic Symbicort)

Formulary Management Review: Initial: April 2020 Revision:



Step Therapy Approval Criteria Eliquis (apixaban)

Generic name: apixaban **Brand name:** Eliquis

Medication class: Factor Xa inhibitor; direct oral anticoagulant

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

• Previous failure of Xarelto in the past 365 days.

Formulary Management Review: Initial: April 2020 Revision:



Step Therapy Approval Criteria Enbrel (etanercept)

Generic name: etanercept **Brand name:** Enbrel

Medication class: TNF inhibitor; immune suppressant

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

- Previous failure of one of the following in the past 365 days:
 - Asacol
 - Balsalazide
 - o Dipentum
 - Methotrexate
 - o Rowasa
 - Azathioprine
 - Cyclosporine
 - o Hydroxychloroquine
 - o Hydroxyurea
 - o Leflunomide
 - Mercaptopurine
 - Soriatane
 - Sulfasalazine

Formulary Management Review: Initial: October 2013

Revision: April 2015, October 2016



Step Therapy Approval Criteria Envarsus XR (tacrolimus extended-release)

Generic name: tacrolimus extended-release

Brand name: Envarsus XR

Medication class: Calcineurin inhibitor

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

• Previous failure of tacrolimus capsules in the past 365 days.

Formulary Management Review: Initial: April 2020



Step Therapy Approval Criteria Estring (estradiol vaginal ring)

Generic name: estradiol vaginal ring

Brand name: Estring

Medication class: Hormone replacement therapy

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of estradiol vaginal cream in the past 365 days.

Formulary Management Review: Initial: November 2019 Revision:



Step Therapy Approval Criteria Estrogel (estradiol)

Generic name: estradiol **Brand name:** Estrogel

Medication class: Hormone replacement therapy

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

- Previous failure of one of the following in the past 365 days:
 - Estradiol oral tablets
 - o Estradiol transdermal patches
 - o Estradiol vaginal cream

Formulary Management Review: Initial: February 2020 Revision:



Step Therapy Approval Criteria Eucrisa (crisaborole)

Generic name: crisaborole **Brand name:** Eucrisa

Medication class: Antiinflammatory; PDE-4 inhibitor

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of one formulary topical corticosteroid in the past 365 days.

Step 2:

• Previous failure of tacrolimus ointment in the past 365 days.

Formulary Management Review: Initial: November 2019 Revision:

Ne visioii.



Step Therapy Approval Criteria Femring (estradiol vaginal ring)

Generic name: estradiol vaginal ring

Brand name: Femring

Medication class: Hormone replacement therapy

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of estradiol vaginal cream in the past 365 days.

Formulary Management Review: Initial: May 2020



Step Therapy Approval Criteria Fiasp (insulin aspart, recombinant)

Generic name: insulin aspart, recombinant

Brand name: Fiasp
Medication class: Insulin

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

- Previous failure of both of the following in the past 365 days:
 - o Insulin lispro
 - Novolog

Formulary Management Review: Initial: April 2020



Step Therapy Approval Criteria Humira (adalimumab)

Generic name: adalimumab

Brand name: Humira

Medication class: TNF inhibitor; monoclonal antibody; antirheumatic

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

- Previous failure of one of the following in the past 365 days:
 - Asacol
 - Balsalazide
 - o Dipentum
 - Methotrexate
 - o Rowasa
 - Azathioprine
 - o Cyclosporine
 - o Hydroxychloroquine
 - o Hydroxyurea
 - o Leflunomide
 - Mercaptopurine
 - Soriatane
 - Sulfasalazine

Formulary Management Review: Initial: October 2013

Revision: April 2015, October 2016



Step Therapy Approval Criteria Imitrex Injection vial and STATdose (sumatriptan succinate)

Generic name: sumatriptan

Brand name: Imitrex Injection vial and Imitrex STATdose

Medication class: 5HT-1 serotonin receptor agonist; antimigraine

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of sumatriptan oral tablets or sumatriptan nasal spray in the past 365 days

Additional considerations:

• Quantity limit (QL) of 6 doses (3 ml) per 30 days

Formulary Management Review: Initial: October 2013



Step Therapy Approval Criteria Invokana (canagliflozin)

Generic name: can agliflozin **Brand name:** Invokana

Medication class: SGLT2 inhibitor

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of Farxiga in the past 365 days.

Formulary Management Review:

Initial: July 2019

Revision: October 2020



Step Therapy Approval Criteria Jardiance (empagliflozin)

Generic name: empagliflozin

Brand name: Jardiance

Medication class: SGLT2 inhibitor

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of Farxiga in the past 365 days.

Formulary Management Review:

Initial: July 2017

Revision: October 2020



Step Therapy Approval Criteria Levitra (vardenafil)

Generic name: vardenafil **Brand names:** Levitra

Medication class: Phosphodiesterase-5 (PDE-5) inhibitor

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of sildenafil citrate (generic for Viagra) in the past 365 days

Additional considerations:

• Quantity Limit (QL) of 6 tablets per 30 days

Formulary Management Review: Initial: July 2018 Revision:



Step Therapy Approval Criteria Lumigan (bimatoprost)

Generic name: bimatoprost **Brand name:** Lumigan

Medication class: Anti-glaucoma

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

- Previous failure of both of the following in the past 365 days:
 - Latanoprost
 - Travoprost

Formulary Management Review: Initial: August 2020



Step Therapy Approval Criteria Mydayis (dextroamphetamine/amphetamine)

Generic name: dextroamphetamine/amphetamine

Brand name: Mydayis

Medication class: ADHD agent; CNS stimulant

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of a formulary generic amphetamine product (such as generic Adderall or generic Dexedrine) in the past 365 days

Step 2:

• Previous failure of formulary generic methylphenidate product (such as generic Ritalin, generic Concerta or generic Focalin) in the past 365 days

Formulary Management Review: Initial: February 2020 Revision:



Step Therapy Approval Criteria Myrbetriq (mirabegron)

Generic name: mirabegron **Brand name:** Myrbetriq

Medication class: Overactive bladder

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

- Previous failure of one of the following in the past 365 days:
 - Oxybutynin (immediate release or extended release)
 - o Tolterodine (immediate release or extended release)

Formulary Management Review: Initial: January 2020 Revision:



Step Therapy Approval Criteria Nucynta ER (tapentadol extended-release)

Generic name: tapentadol extended-release

Brand name: Nucynta ER
Medication class: Analgesic

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

• Previous failure of tramadol extended-release tablets in the past 365 days.

Formulary Management Review:

Initial: April 2020 Revision: October 2020



Step Therapy Approval Criteria Nucynta (tapentadol)

Generic name: tapentadol
Brand name: Nucynta
Medication class: Analgesic

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

• Previous failure of tramadol immediate-release tablets in the past 365 days.

Formulary Management Review: Initial: October 2020 Revision:



Step Therapy Approval Criteria Onfi (clobazam)

Generic name: clobazam

Brand name: Onfi

Medication class: Anticonvulsant

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

- Previous failure of both of the following in the past 365 days:
 - o Lamotrigine
 - o Topiramate

Formulary Management Review: Initial: July 2019



Step Therapy Approval Criteria Ozempic (semaglutide)

Generic name: semaglutide **Brand name:** Ozempic

Medication class: GLP-1 receptor agonist

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of Trulicity in the past 365 days.

Formulary Management Review: Initial: February 2020



Step Therapy Approval Criteria Pristiq (desvenlafaxine succinate)

Generic name: desvenlafaxine succinate

Brand name: Pristiq

Medication class: Antidepressant

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of venlafaxine in the past 365 days.

Formulary Management Review: Initial: November 2020



Step Therapy Approval Criteria Protopic (tacrolimus)

Generic name: tacrolimus **Brand names:** Protopic

Medication class: Calcineurin inhibitor

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of one formulary topical corticosteroid in the past 365 days

Additional considerations:

• Quantity Limit (QL) of 100 grams per 30 days

Formulary Management Review: Initial: April 2017 Revision:



Step Therapy Approval Criteria Qbrexza (glycopyrronium)

Generic name: glycopyrronium

Brand name: Qbrexza

Medication class: Topical anticholinergic

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of Drysol in the past 365 days.

Formulary Management Review: Initial: February 2020



Step Therapy Approval Criteria Risperdal Consta (risperidone long-acting injectable)

Generic name: risperidone long-acting injectable

Brand name: Risperdal Consta

Medication class: Atypical antipsychotic

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of risperidone tablets in the past 365 days.

Formulary Management Review: Initial: July 2017 Revision:



Step Therapy Approval Criteria Tirosint (levothyroxine)

Generic name: levothyroxine

Brand name: Tirosint Medication class: Thyroid

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

• Previous failure of levothyroxine tablets in the past 365 days.

Formulary Management Review: Initial: April 2020



Step Therapy Approval Criteria Toujeo Solostar and Toujeo Max Solostar (insulin glargine)

Generic name: insulin glargine

Brand name: Toujeo Solostar and Toujeo Max Solostar

Medication class: Insulin

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of Lantus and Levemir in the past 365 days.

Formulary Management Review: Initial: February 2020 Revision:



Step Therapy Approval Criteria Trelegy Ellipta (fluticasone/vilanterol/umeclidinium)

Generic name: fluticasone/vilanterol/umeclidinium

Brand name: Trelegy Ellipta

Medication class: Inhaled glucocorticoid/long-acting beta-agonist/long-acting muscarinic

antagonist

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Previous failure of two of the following in the past 365 days

- Fluticasone/salmeterol (generic Advair Diskus) or Advair HFA
- Budesonide/formoterol (generic Symbicort)
- Spiriva Handihaler or Respimat

Formulary Management Review: Initial: April 2020 Revision:



Step Therapy Approval Criteria Vimpat (lacosamide)

Generic name: lacosamide **Brand name:** Vimpat

Medication class: Anticonvulsant

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

- Previous failure of two of the following in the past 365 days:
 - o Carbamazepine
 - o Divalproex sodium or valproic acid
 - Felbamate
 - o Gabapentin
 - o Lamotrigine
 - o Levetiracetam
 - o Oxcarbazepine
 - o Phenobarbital
 - o Phenytoin
 - Pregabalin (Lyrica)
 - o Topiramate
 - o Zonisamide

Formulary Management Review: Initial: October 2019
Revision:



Step Therapy Approval Criteria Vyvanse (lisdexamfetamine)

Generic name: lisdexamfetamine

Brand name: Vyvanse

Medication class: CNS stimulant

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of a formulary generic amphetamine product (such as generic Adderall or generic Dexedrine) in the past 365 days

Step 2:

• Previous failure of formulary generic methylphenidate product (such as generic Ritalin, generic Concerta or generic Focalin) in the past 365 days

Additional considerations:

• Quantity Limit (QL) of 30 capsules per 30 days

Formulary Management Review: Initial: April 2017



Step Therapy Approval Criteria Vyzulta (latanoprostene)

Generic name: latanoprostene

Brand name: Vyzulta

Medication class: Anti-glaucoma

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

- Previous failure of both of the following in the past 365 days:
 - Latanoprost
 - Travoprost

Formulary Management Review: Initial: August 2020



Step Therapy Approval Criteria Xifaxan (rifaximin)

Generic name: rifaximin
Brand name: Xifaxan
Medication class: Rifamycin

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

 Previous failure of lactulose, dicyclomine, ciprofloxacin or azithromycin in the past 180 days

Additional considerations:

- Quantity limit (QL) of 60 tablets per 30 days for the 550 mg tablets
- Quantity limit (QL) of 180 tablets per 30 days for the 200 mg tablets

Formulary Management Review: Initial: July 2015

Revision: October 2017



Step Therapy Approval Criteria Xiidra (lifitegrast)

Generic name: lifitegrast Brand name: Xiidra

Medication class: LFA-1 antagonist

<u>Criteria for use</u>: (steps are all inclusive unless otherwise noted)

Step 1:

• Previous failure of Restasis eye drops in the past 365 days.

Formulary Management Review: Initial: October 2019